Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model
Open Access
- 5 January 2013
- journal article
- research article
- Published by Springer Nature in BMC Urology
- Vol. 13 (1) , 1
Abstract
Background: COX-2 inhibitors have an antitumor potential and have been verified by many researchers. Treatment of cancer cells with external stressors such as irradiation can stimulate the over-expression of COX-2 and possibly confer radiation resistance. In this study, we tested if topical diclofenac, which inhibits both COX-1 and COX-2, administration rendered prostate tumor cells sensitize to the effects of radiation. Methods: LNCaP-COX-2 and LNCaP-Neo cells were treated with 0 to 1000 μM diclofenac. Next, a clonogenic assay was performed in which cells were subjected to irradiation (0 to 4 Gy) with or without diclofenac. COX-2 expression and other relevant molecules were measured by real-time PCR and immunohistochemistry after irradiation and diclofenac treatment. In addition, we assessed the tumor volumes of xenograft LNCaP-COX-2 cells treated with topical diclofenac with or without radiation therapy (RT). Results: LNCaP-COX-2 and LNCaP-Neo cell lines experienced cytotoxic effects of diclofenac in a dose related manner. Clonogenic assays demonstrated that LNCaP-COX-2 cells were significantly more resistant to RT than LNCaP-Neo cells. Furthermore, the addition of diclofenac sensitized LNCaP-COX-2 not but LNCaP-Neo cells to the cytocidal effects of radiation. In LNCaP-COX-2 cells, diclofenac enhanced radiation-induced apoptosis compared with RT alone. This phenomenon might be attributed to enhancement of RT-induced TRAIL expression as demonstrated by real-time PCR analysis. Lastly, tumor volumes of LNCaP-COX-2 cells xenograft treated with diclofenac or RT alone was >4-fold higher than in mice treated with combined diclofenac and radiation (pin vitro and in vivo findings suggest that conventional COX inhibitor, diclofenac enhances the effect of RT on prostate cancer cells that express COX-2. Thus, diclofenac may have potential as radiosensitizer for treatment of prostate cancer.Keywords
This publication has 39 references indexed in Scilit:
- Cyclooxygenases: structural and functional insightsJournal of Lipid Research, 2009
- Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survivalApoptosis, 2008
- Role of Tumor Necrosis Factor-α and TRAIL in High-Dose Radiation–Induced Bystander Signaling in Lung AdenocarcinomaCancer Research, 2007
- A Large Cohort Study of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs and Prostate Cancer IncidenceJNCI: Journal of the National Cancer Institute, 2005
- COX‐3—a virtual pain target in humans?The FASEB Journal, 2003
- COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cellsHepatology, 2002
- A Population-Based Study of Daily Nonsteroidal Anti-inflammatory Drug Use and Prostate CancerMayo Clinic Proceedings, 2002
- Cyclooxygenases: Structural, Cellular, and Molecular BiologyAnnual Review of Biochemistry, 2000
- Enhancement of Tumor Response to -Radiation by an Inhibitor of Cyclooxygenase-2 EnzymeJNCI: Journal of the National Cancer Institute, 1999
- Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2Cell, 1995